Opthea is developing novel biologic inhibitors of angiogenesis (blood vessel growth), lymphangiogenesis (lymphatic vessel growth) and vascular leakage for the treatment of ophthalmic diseases.


Opthea's lead compound, OPT-302, is a soluble receptor that specifically and potently blocks the activity of two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, that are involved in the progression of both retinal and corneal diseases.  


Opthea is currently developing OPT-302 for the treatment of wet age-related macular degeneration (wet AMD).


Opthea Pty Ltd is a private, 100% owned subsidiary of Circadian Technologies Limited based in Melbourne, Australia.  Enquiries can be directed to: info@opthea.com


July 10 2015 - Bioshares - Clarus Ventures Eyes Circadian Technologies Read More...

Merger Market Report - Circadian Technologies - July 6 2015 Read More...

17 June 2015, Melbourne, Australia: Circadian Technologies (ASX:CIR) has feature Read More...


To receive notifications about Opthea, subscribe to our distribution list.